← Home / Travere Therapeutics, Inc. (TVTX)
Stock Analysis

Travere Therapeutics, Inc. (TVTX)

TVTX
TVTX · Healthcare • Biotechnology
65.36 -0.53%
Track TVTX in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when TVTX price is:
52W Range Position
99%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-24 17:53 UTC
WOI Investment Thesis
Constructive
Watch confirmation and structural levels before acting.
⚖️
✓
Fundamentals
Strong / Negative
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
No reliable structural support level is currently available.
Not available
↗
Break Above
Primary setup trigger already cleared; this level remains the breakout reference.
65.12
🎯
Next Objective
Primary pattern objective while the setup remains active.
78.36
×
Thesis Break
Primary technical setup invalidates below this level.
Below 60.20
Recent Company Events
SEC VERIFIED
Latest material filings
AUG
4
●
Financial Results
HIGH
TVTX reports financial results
On August 4, 2026 , Travere Therapeutics, Inc.
8-K Filing • SEC EDGAR
JUL
9
●
Management / Board
MEDIUM
TVTX board and management update
5.02(b) On July 6, 2026, Sandra Calvin, chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, provided notice to the Company of her intention to retire from employment with the Company following the filing of the Company’s Annual Report on Form 10-K expected in February 2027 (the “Ret...
8-K Filing • SEC EDGAR
JUN
16
●
Management / Board
MEDIUM
TVTX board and management update
On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027 (the “Retirement Date”), the 10 year anniversary of his employment with the Company.
8-K Filing • SEC EDGAR
What's Driving TVTX?
✓ Technical setup is active
Momentum is Neutral. Primary trigger is Above 65.12 with structure risk at Below 60.20.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
Below 60.20
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
A confirmed technical structure is active. Use its trigger, target and invalidation levels for context.
Pattern
Bull Flag · Confirmed
Trigger
65.12
Target
78.36
Invalidation
60.20
RSI(14)
65.8
Price Chart
TVTX — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-21
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$6.1B
Company size
EV
$6.2B
Debt-adjusted value
P/S
10.3
Premium
P/B
60.4
Very high
EV/Sales
10.5
Premium
FCF Yield
-0.30%
Cash return
Not financial advice
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Mixed
⚖
Balance Sheet
Manageable
💵 Revenue
169.58M
↗ Strong
📈 Net Income
-34.80M
↘ Negative
🧮 EPS (Basic)
-0.37
↘ Negative
Travere Therapeutics, Inc.
Healthcare • Biotechnology
You Might Also Like